An exome-wide association study involving almost 2,800 individuals with dilated cardiomyopathy led to six new and two known susceptibility loci.
The company plans to open a $20 million Series C round in Q2 of this year and launch a study to support a US Food and Drug Administration submission in mid-2018.
The study will involve assaying proteomic markers for dementias including Alzheimer's disease, and understanding genomic markers as part of the normal aging process.
The researchers believe that by monitoring mtDNA copy number in blood, they will be able to identify people at risk for developing CHD who could benefit from preventative efforts.
A number of these loci were linked to blood pressure medication targets, and the researchers developed a genetic risk score.
Multi-omics, mass spec-based imaging, and cardiovascular biomarkers received extra attention at MSACL US while small molecules continue to drive the field.
Singulex's CEO provided an update at the JP Morgan Healthcare conference on the firm's progress in developing its immunodiagnostics platform.
The company will develop a data warehouse that integrates whole-genome sequence, medical, and wearables data from patients and controls.
By studying variants in PCSK9, researchers reported the therapies targeting the gene would have some of the same effects as statins.
In a new AMP working group project, labs can volunteer to compare their interpretation of challenging variants to help identify where and how the guidelines might be improved.
An international team of researchers examined genetic and lifestyle factors linked to heart disease in some 55,600 people.
The researchers found that genetically predicted increases in heart rate were associated with shortened lifespans.
The effort aims to identify a suite of markers that could aid in management of type II diabetes and related conditions like retinopathy and kidney damage.
A team of researchers from Brigham and Women's Hospital and Harvard Medical School found that the two proteins appear to have opposing effects.
The companies will use Myriad RBM's CustomMAP platform to measure cardiovascular risk biomarkers in patients treated with a Sanofi diabetes drug.
The first apps will be for individuals at low risk for inherited forms of cancer and heart disease, and will require a doctor's permission.
Investigators plan to expand the program nationwide, with the hope that it can help guide care for living family members and further understanding of causal diseases.
The company has signed an agreement with a hospital group in Northern California and will be offering its test, named StatRes, at the group's seven facilities.
Some six months after establishing itself as an independent entity, the company plans to roughly double its protein biomarker libraries by the end of the year.
An analysis focused on large, rare de novo CNVs has identified copy number changes contributing to conotruncal heart disease in Chinese individuals.
While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.
Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.
In Nature this week: paternal age associated with de novo mutations in children, and more.
Nature News writes that researchers are still wrangling over the role of the p-value.